Metabolic syndrome: do clinical criteria identify similar individuals among overweight premenopausal women?

Metabolism: Clinical and Experimental

Volumn 57, Issue 1, 2008, Pages 49-56

  Alhassan, Sofiya ^a,b   Kiazand, Alexandre ^a   Balise, Raymond R ^a   King, Abby C ^a   Reaven, Gerald M ^a   Gardner, Christopher D ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; DIETARY INTAKE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; OBESITY; PREMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; WORLD HEALTH ORGANIZATION;

BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; BODY SIZE; CHOLESTEROL, HDL; DIET, REDUCING; FEMALE; HUMANS; METABOLIC SYNDROME X; OBESITY; OVERWEIGHT; PREMENOPAUSE; TRIGLYCERIDES; UNITED STATES;

EID: 37049006915     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2007.08.006     Document Type: Article

References (55)

1. Thom T., Haase N., Rosamond W., et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation l113 (2006) e85-e151
2. American Heart Association. Heart disease and stroke statistics-2004 update (2003), American Heart Association, Dallas
3. Carr D.B., Utzschneider K.M., Hull R.L., et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes l53 (2004) 2087-2094
4. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation l106 (2002) 3143-3421
5. Wilson P.W., Kannel W.B., Silbershatz H., and D'Agostino R.B. Clustering of metabolic factors and coronary heart disease. Arch Intern Med 159 (1999) 1104-1109
6. Ford E.S. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of evidence. Diabetes Care l28 (2005) 1769-1778
7. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med l15 (1998) 539-553
8. Balkau B., and Charles M. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med l16 (1999) 442-443
9. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care l26 (2003) 3160-3167
10. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation l112 (2005) 2735-2752
11. Zimmet P., Alberti G., and Shaw J. A new IDF worldwide definition of the metabolic syndrome: the rational and the results. Diabetes Voice l50 (2005) 31-33
12. McLaughlin T., Abbasi F., Cheal K., Chu J., Lamendola C., and Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med l139 (2003) 802-809
13. Reaven G.M. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr l25 (2005) 391-406
14. Kahn H.S., and Valdez R. Metabolic risks identified by the combination of enlarged waist and elevated triacylglycerol concentration. Am J Clin Nutr l78 (2003) 928-934
15. Lemieux I., Pascot A., Couillard C., et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?. Circulation l102 (2000) 179-184
16. Tanko L.B., Bagger Y.Z., Qin G., Alexandersen P., Larsen P.J., and Christiansen C. Enlarged waist combined with elevated triglycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women. Circulation l111 (2005) 1883-1890
17. McLaughlin T., Allison G., Abbasi F., Lamendola C., and Reaven G.M. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism l53 (2004) 495-499
18. Ford E.S. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the US. Diabetes Care l28 (2005) 2745-2749
19. Ford E.S., and Giles W.H. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care l26 (2003) 575-581
20. Alvarez C.A., Lopez F.V., Suarez G.S., Arias G.T., Prieto D.M., and Diaz G.L. Differences in the prevalence of the metabolic syndrome according to the ATP-III and WHO definition. Med Clin (Barc) l124 (2005) 368-370
21. Guerrero-Romero F., and Rodriguez-Moran M. Concordance between the 2005 International Diabetes Federation definition for diagnosing metabolic syndrome with the National Cholesterol Education Program Adult Treatment Panel III and the World Health Organization definitions. Diabetes Care l28 (2005) 2588-2589
22. Meigs J.B., Wilson P.W., Nathan D.M., D'Agostino R.B., Williams K., and Haffner S.M. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes l52 (2003) 2160-2167
23. Dekker J.M., Girman C., Rhodes T., et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation l112 (2005) 666-673
24. de Simone G., Devereux R.B., Chinali M., et al. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study. Diabetes Care l30 (2007) 1851-1856
25. Lorenzo C., Williams K., Hunt K.J., and Haffner S.M. The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care l30 (2007) 8-13
26. Klein S., Burke L.E., Bray G.A., et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation l110 (2004) 2952-2967
27. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. Obes Res l6 (1998) 51S-209S
28. Gardner C.D., Kiazand A., Alhassan S., et al. Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial. JAMA l297 (2007) 969-977
29. Atkins R. Dr Atkins' new diet revolution (2002), Harper Collins Inc, New York
30. Brownell K. The LEARN program for weight management (2000), American Health Publishing Company, Dallas
31. Ornish D. Eat more weigh less (2001), Harper Collins Inc., New York
32. Sears B., and Lawren W. Enter the zone: a dietary road map to lose weight permanently: reset your genetic code: prevent disease: achieve maximum physical performance (1995), Harper Collins Inc., New York
33. American College of Sports Medicine: physical fitness testing and interpretation. In: Franklin B. (Ed). ACSM's guidelines for exercise testing and prescription Vol. 6 (2000), Williams & Wilkins, Philadelphia 57-90
34. King A.C., Sallis J.F., Dunn A.L., et al. Overview of the Activity Counseling Trial (ACT) intervention for promoting physical activity in primary health care settings. Activity Counseling Trial Research Group. Med Sci Sports Exerc l30 (1998) 1086-1096
35. Sampson E., Dumers L., and Krieg A. Faster enzymatic procedure for serum triglycerides. Clin Chem l21 (1975) 1983-1985
36. Warnick G., and Albers J. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high-density lipoprotein cholesterol. J Lipid Res l19 (1978) 65-76
37. Allain C., Poon L., Chan C., Richmond W., and Fu P. Enzymatic determination of total serum cholesterol. Clin Chem l20 (1974) 470-475
38. Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem l6 (1969) 24-27
39. Lott J.A., and Turner K. Evaluation of Trinder's glucose oxidase method for measuring glucose in serum and urine. Clin Chem l21 (1975) 1754-1760
40. Morgan C.R., and Lazarow A. Immunoassay of insulin: two antibody system: plasma insulin levels in normal, subdiabetic and diabetic rats. Diabetes l12 (1963) 115-126
41. Hunt K.J., Resendez R.G., Williams K., Haffner S.M., and Stern M.P. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation l110 (2004) 1251-1257
42. Yeni-Komshian H., Carantoni M., Abbasi F., and Reaven G.M. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care l23 (2000) 171-175
43. Landis J.R., and Koch G.G. The measurement of observer agreement for categorical data. Biometrics l33 (1977) 159-174
44. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care l24 (2001) 683-689
45. Hanley A.J., Karter A.J., Williams K., et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation l112 (2005) 3713-3721
46. Serebruany V.L., Miller M., Pokov A.N., et al. Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study). Am J Cardiol l97 (2006) 1332-1336
47. Diercks G.F., van Boven A.J., Hillege J.L., de Jong P.E., Rouleau J.L., and van Gilst W.H. The importance of microalbuminuria as a cardiovascular risk indicator: a review. Can J Cardiol l18 (2002) 525-535
48. Prior J.C. Perimenopause: the complex endocrinology of the menopausal transition. Endocr Rev 19 (1998) 397-428
49. Lakka H.-M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA l288 (2002) 2709-2716
50. Wilson P.W., D'Agostino R.B., Parise H., Sullivan L., and Meigs J.B. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation l112 (2005) 3066-3072
51. Castelli W., Doyle J., Hames C., et al. HDL cholesterol and other lipids in coronary heart disease: the cooperative lipoprotein phenotyping study. Circulation l55 (1977) 767-772
52. Escobar E. Hypertension and coronary heart disease. J Hum Hypertens l16 Suppl 1 (2002) S61-S63
53. Poirier P., Giles T.D., Bray G.A., et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol l26 (2006) 968-976
54. Schnell O., and Standl E. Impaired glucose tolerance, diabetes, and cardiovascular disease. Endocr Pract l12 Suppl 1 (2006) 16-19
55. Reaven G.M. The metabolic syndrome: is this diagnosis necessary?. Am J Clin Nutr l83 (2006) 1237-1247